Wedbush Forecasts Biogen’s Q2 Earnings (NASDAQ:BIIB)

Biogen Inc. (NASDAQ:BIIB) – Analysts at Wedbush upped their Q2 2025 EPS estimates for Biogen in a research note issued on Wednesday, April 16th. Wedbush analyst L. Chico now anticipates that the biotechnology company will post earnings per share of $4.21 for the quarter, up from their prior forecast of $3.98. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. Wedbush also issued estimates for Biogen’s Q3 2025 earnings at $4.12 EPS, Q4 2025 earnings at $3.87 EPS, FY2025 earnings at $15.71 EPS, Q3 2026 earnings at $4.33 EPS, FY2028 earnings at $20.48 EPS and FY2029 earnings at $21.14 EPS.

Biogen (NASDAQ:BIIB) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%.

A number of other equities research analysts have also recently weighed in on BIIB. Canaccord Genuity Group dropped their price target on Biogen from $298.00 to $265.00 and set a “buy” rating for the company in a report on Thursday, February 13th. Truist Financial lowered their price objective on shares of Biogen from $220.00 to $210.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. BMO Capital Markets dropped their price target on Biogen from $156.00 to $139.00 and set a “market perform” rating on the stock in a research note on Thursday, February 13th. Piper Sandler reissued a “neutral” rating and issued a $135.00 target price (down previously from $138.00) on shares of Biogen in a research report on Tuesday, February 18th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Biogen in a report on Wednesday. Eighteen investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $213.15.

Biogen Stock Up 2.9 %

BIIB opened at $118.61 on Friday. Biogen has a fifty-two week low of $110.04 and a fifty-two week high of $238.00. The company has a market capitalization of $17.36 billion, a P/E ratio of 10.60, a P/E/G ratio of 1.51 and a beta of 0.06. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.35 and a quick ratio of 0.90. The firm’s fifty day moving average price is $134.71 and its two-hundred day moving average price is $152.19.

Insider Buying and Selling at Biogen

In related news, Director Stephen A. Sherwin sold 8,760 shares of the firm’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $150.02, for a total value of $1,314,175.20. Following the transaction, the director now owns 11,318 shares of the company’s stock, valued at approximately $1,697,926.36. This trade represents a 43.63 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Biogen

A number of institutional investors have recently added to or reduced their stakes in BIIB. Virtu Financial LLC purchased a new stake in shares of Biogen during the 3rd quarter valued at approximately $4,111,000. World Investment Advisors LLC bought a new stake in shares of Biogen during the 3rd quarter worth $1,118,000. Wilmington Savings Fund Society FSB bought a new position in shares of Biogen during the 3rd quarter valued at about $150,000. Tidal Investments LLC lifted its position in Biogen by 13.6% in the 3rd quarter. Tidal Investments LLC now owns 9,012 shares of the biotechnology company’s stock worth $1,747,000 after buying an additional 1,082 shares during the last quarter. Finally, Synovus Financial Corp grew its position in Biogen by 6.0% during the third quarter. Synovus Financial Corp now owns 14,462 shares of the biotechnology company’s stock valued at $2,803,000 after acquiring an additional 821 shares during the last quarter. 87.93% of the stock is owned by institutional investors.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.